Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 7/20 | 0.62 |
| ▸ | KMO | O15229 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18905235 | 0.81 | KMO (0.68) | CYP2A6KMOCYP3A4CYP1A2CLK4 | |
| SCHEMBL2129077 | 0.79 | ASIC3 (0.59) | KMOCYP1A2MEN1KMT2ACYP2C19 | |
| SCHEMBL30412356 | 0.79 | ASIC3 (0.59) | KMOCYP1A2MEN1KMT2ACYP2C19 | |
| SCHEMBL1444763 | 0.79 | MIF (0.65) | CYP2A6KMOCYP3A4CYP1A2CLK4 | |
| SCHEMBL31205777 | 0.79 | KMO (0.59) | CYP2A6KMOCYP3A4CYP1A2CLK4 | |
| SCHEMBL24151512 | 0.79 | KMO (0.59) | CYP2A6KMOCYP3A4CYP1A2CLK4 | |
| SCHEMBL558195 | 0.79 | ASIC3 (0.65) | CYP2A6KMOCYP3A4CYP1A2CLK4 | |
| SCHEMBL30507429 | 0.79 | ASIC3 (0.65) | CYP2A6KMOCYP3A4CYP1A2CLK4 | |
| SCHEMBL20816293 | 0.78 | CYP1A2 (0.62) | CYP2A6KMOCYP3A4CYP1A2CLK4 | |
| SCHEMBL10220550 | 0.78 | KMO (0.55) | CYP2A6KMOCYP3A4CYP1A2CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9666807-B2 | Organic light emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-05-30 | — | — | US | disclosed |
| US-9666807-B2 | Organic light emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-05-30 | — | — | US | disclosed |
| US-20160101104-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-14 | — | — | US | disclosed |
| US-20160028017-A1 | ORGANIC LIGHT EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-01-28 | — | — | US | disclosed |
| US-20150342935-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150094309-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-02 | — | — | US | disclosed |
| US-20140221377-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL MYERS SQUIBB CO (US) | 2014-08-07 | — | — | US | disclosed |
| WO-2011053292-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-05 | — | — | WO | disclosed |
| WO-2009131926-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221377-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | CYP2A6 2357/4885KMO 932/4885CYP3A4 2815/4885 |
| US-20160101104-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | CYP2A6 2357/4885KMO 932/4885CYP3A4 2815/4885 |
| US-20150342935-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | CYP2A6 2357/4885KMO 932/4885CYP3A4 2815/4885 |
| US-20150094309-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | CYP2A6 2357/4885KMO 932/4885CYP3A4 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.